No. 1 Antiemetic
Ondeed-MD4 TabletsNOW TREAT NAUSEA AND VOMITING WITH CONFIDENCE
Ondansetron 4 mg Mouth Dissolving Tablets
Ondeed-MD4 is a powerful and selective antagonist at 5-HT3 receptors. It works both centrally and peripherally to block the initiation of emetic reflexes, making it highly effective in treating nausea and vomiting caused by various conditions.
With a receptor affinity 250–1000 times greater than other targets, it provides precise action with minimal side effects. Its mouth-dissolving format ensures rapid onset and ease of use, especially beneficial in pediatric and emergency settings.
- Selective antagonist at 5—HT3 receptors
- Affinity 250—1000 times greater than for any other receptor
- Antagonizes receptors both centrally and peripherally
- Blocks even the initiation of emetic reflexes
Indications :
- Nausea & Vomating
- Diarrhoea
- Gastro-enterities
- Post-Surgery
- Drugs
- Dehydration
Ondansetron 4 mg is a serotonin 5-HT3 receptor antagonist. Its quick-dissolving formulation allows rapid absorption through the oral mucosa, ensuring fast relief from nausea and vomiting symptoms.
Ondeed-MD4 provides dependable antiemetic action in both children and adults. It enables effective oral rehydration by reducing vomiting episodes, and supports recovery from gastrointestinal and post-treatment side effects.
Use as directed by Physician.
Ondeed-MD4 selectively blocks 5-HT3 receptors, both in the gastrointestinal tract and the brain. This prevents the initiation and progression of nausea and vomiting, offering rapid and reliable relief even in challenging conditions like post-surgery or chemotherapy.
Ondeed-MD4 is indicated for nausea and vomiting associated with gastroenteritis, dehydration, postoperative care, drug-induced reactions, diarrhea. It is also well suited for use in emergency pediatric care.
Place one mouth-dissolving tablet on the tongue and allow it to dissolve completely. Do not chew or swallow with water. Follow your physician’s dosage instructions, especially for children and elderly patients.
